Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.
Department of Rheumatology, Cantonal Hospital, Fribourg, Switzerland.
Ann Rheum Dis. 2017 Feb;76(2):318-328. doi: 10.1136/annrheumdis-2016-209724. Epub 2016 Jul 4.
The original European League Against Rheumatism recommendations for managing fibromyalgia assessed evidence up to 2005. The paucity of studies meant that most recommendations were 'expert opinion'.
A multidisciplinary group from 12 countries assessed evidence with a focus on systematic reviews and meta-analyses concerned with pharmacological/non-pharmacological management for fibromyalgia. A review, in May 2015, identified eligible publications and key outcomes assessed were pain, fatigue, sleep and daily functioning. The Grading of Recommendations Assessment, Development and Evaluation system was used for making recommendations.
2979 titles were identified: from these 275 full papers were selected for review and 107 reviews (and/or meta-analyses) evaluated as eligible. Based on meta-analyses, the only 'strong for' therapy-based recommendation in the guidelines was exercise. Based on expert opinion, a graduated approach, the following four main stages are suggested underpinned by shared decision-making with patients. Initial management should involve patient education and focus on non-pharmacological therapies. In case of non-response, further therapies (all of which were evaluated as 'weak for' based on meta-analyses) should be tailored to the specific needs of the individual and may involve psychological therapies (for mood disorders and unhelpful coping strategies), pharmacotherapy (for severe pain or sleep disturbance) and/or a multimodal rehabilitation programme (for severe disability).
These recommendations are underpinned by high-quality reviews and meta-analyses. The size of effect for most treatments is relatively modest. We propose research priorities clarifying who will benefit from specific interventions, their effect in combination and organisation of healthcare systems to optimise outcome.
最初的欧洲抗风湿病联盟管理纤维肌痛的建议评估了截至 2005 年的证据。由于研究数量较少,大多数建议都是“专家意见”。
来自 12 个国家的一个多学科小组评估了证据,重点是关于药物治疗/非药物治疗纤维肌痛的系统评价和荟萃分析。2015 年 5 月的一项审查确定了合格的出版物,评估的关键结果是疼痛、疲劳、睡眠和日常功能。使用推荐评估、制定和评估系统(Grading of Recommendations Assessment, Development and Evaluation system)进行推荐。
共确定了 2979 个标题;从中选择了 275 篇全文进行审查,评估了 107 篇综述(和/或荟萃分析)作为合格的。基于荟萃分析,指南中唯一基于治疗的“强烈推荐”疗法是运动。基于专家意见,提出了一种逐步的方法,建议分四个主要阶段进行,以与患者共同决策为基础。初始管理应包括患者教育,重点是非药物治疗。如果没有反应,应根据个人的具体需求,进一步采用其他治疗方法(所有这些方法都基于荟萃分析评估为“弱推荐”),可能包括心理治疗(用于情绪障碍和无益的应对策略)、药物治疗(用于严重疼痛或睡眠障碍)和/或多模式康复计划(用于严重残疾)。
这些建议是基于高质量的综述和荟萃分析。大多数治疗方法的效果相对较小。我们提出了研究重点,阐明了谁将受益于特定的干预措施,它们在组合中的效果以及优化结果的医疗保健系统的组织。